ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the role and application of flow cytometry in the diagnosis of non-Hodgkin lymphoma (NHL).</p><p><b>METHODS</b>Fresh cell samples from 40 cases of lymphoproliferative disorders were obtained by fine needle aspiration or excisional biopsies. Multiparameter flow cytometry was used to study the surface antigens of lymphoid cells. The immunophenotyping results were also correlated with morphologic features seen in the cytology preparations.</p><p><b>RESULTS</b>Of the 40 cases with histologic diagnosis of NHL, 37 cases (92.5%) had the lymphoma diagnosis confirmed by this method. The concordance rate for the 20 cases of B-cell NHL was 100%. As for the 17 cases with histologic diagnosis of T-cell NHL, 12 cases (66.7%) were correctly diagnosed as T-cell NHL using flow cytometry, while 2 cases (11.8%) were interpreted as B-cell NHL and the remaining 3 cases (17.6%) were undiagnosed.</p><p><b>CONCLUSION</b>Immunophenotyping by flow cytometry can serve as an ancillary technique in diagnosis and subclassification of NHL.</p>
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Biopsy, Fine-Needle , Flow Cytometry , Methods , Immunophenotyping , Lymphoma, B-Cell , Diagnosis , Allergy and Immunology , Pathology , Lymphoma, Non-Hodgkin , Diagnosis , Allergy and Immunology , Pathology , Lymphoma, T-Cell , Diagnosis , Allergy and Immunology , Pathology , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
<p><b>OBJECTIVE</b>To investigate the clinical characteristics of diffuse large B-cell lymphoma (DLBCL) and the factors affecting its prognosis.</p><p><b>METHODS</b>From 1994 to 2002, 138 patients with DLBCL were confirmed by morphological and immunohistochemical examination. Sex, age, clinical stage, performance status (PS), serum lactate dehydrogenase (LDH), number of extranodal lesions, treatment response, cycles of chemotherapy, B symptom, erythrocyte sedimentation rate (ESR), 5-year survival rate and median survival time (mST) were included as the analysis indeces.</p><p><b>RESULTS</b>Lymph nodes were involved in 87.7% of the patients, and extranodal lesions were found in 60.1%. Five-year survival rate was 41.3% for the entire group. Age, stage, PS, serum LDH, number of extranodal lesions, international prognostic index (IPI) and remission rates were significantly correlated with overall survival (OS) and mST (P < 0.05), However, sex, chemotherapy cycles, B symptom, ESR were not related to OS and mST (P > 0.05). Age, stage, remission rates were identified as independent factors affecting the prognosis. Combination of surgery and chemotherapy was quite impressive in the prolongation of survival of patients with extranodal lesions and gastrointestinal lymphoma compared to those by chemotherapy alone.</p><p><b>CONCLUSION</b>Age, stage, PS, serum LDH, number of extranodal lesions, IPI, chemotherapy cycles and remission rates are significant factors affecting the prognosis in DLBCL patients. Age less than 40 years or >/= 65 years, Stage III-IV, partial remission or progressive disease are demonstrated as poor prognostic factors. Combined treatment is the strategy suggested for DLBCL patients with extranodal lesions.</p>
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Combined Modality Therapy , Cyclophosphamide , Therapeutic Uses , Doxorubicin , Therapeutic Uses , Follow-Up Studies , L-Lactate Dehydrogenase , Blood , Lymphatic Metastasis , Lymphoma, B-Cell , Mortality , Pathology , Therapeutics , Lymphoma, Large B-Cell, Diffuse , Mortality , Pathology , Therapeutics , Neoplasm Staging , Prednisone , Therapeutic Uses , Prognosis , Remission Induction , Survival Analysis , Survival Rate , Treatment Outcome , Vincristine , Therapeutic UsesABSTRACT
Objective To clone human asparagine synthetase(ASNS)gene,express the MS2- ASNS fusion protein through gene engineering and use the purified target protein to immune BALB/C mice, prepare and identify the monoclonal antibody(McAb),which forms the base for studying mechanism of L- asparaginase used as salvage regimen in midline NK/T cell lymphoma nasal type.Methods ASNS gene fragment was amplified by RT-PCR from HepG2 cell line and constructed into prokaryocytic expression vector.Fusion-protein of MS2-ASNS was expressed and used for immunizing BALB/C mice to prepare McAbs against ASNS.Identified the McAb and detected the expression of ASNS in tumor.Results Part of the ASNS reading frame(NCBI,M27396:179-1 420 bp)was cloned and product length of RT-PCR was 1 263 bp.Molecular weight of MS2-ASNS was about 54 700 Da.Two strains of hybridoma secreting ASNS McAbs were obtained.The subtype of the ASNS McAb was IgG2a.Western-blot showed that the McAbs could specifically react with MS2-ASNS fusion protein and ASNS protein in tumor cell lines.ASNS expression was detected by immunocytochemistry and Immunohistochemisrry.Conclusion We have cloned human ASNS gene,obtained the anti-ASNS McAb and examined the expression of ASNS in tumor.